Last reviewed · How we verify
AND017 single dose — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AND017 single dose (AND017 single dose) — Kind Pharmaceuticals LLC.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AND017 single dose TARGET | AND017 single dose | Kind Pharmaceuticals LLC | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AND017 single dose CI watch — RSS
- AND017 single dose CI watch — Atom
- AND017 single dose CI watch — JSON
- AND017 single dose alone — RSS
Cite this brief
Drug Landscape (2026). AND017 single dose — Competitive Intelligence Brief. https://druglandscape.com/ci/and017-single-dose. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab